medical weight loss programs – Diet Business Watch

Weight Watchers Collaborates With Google Health Enterprise

October 1, 2026 Weight Watchers announced a collaboration with Google Health Enterprise, combining wearable technology and AI-powered health insights with Weight Watchers’ clinical weight health program. Available now through select Weight Watchers for Business client programs, this collaboration provides employers and payers a new way to activate their weight health benefits, helping more members get […]

Weight Watchers Collaborates With Google Health Enterprise Read More »

Weight Watchers Reports Q1 2026 Results

News / John LaRosa

May 7, 2026 According to management: “We remain confident in our strategy to build the industry-leading weight health platform. Our focus is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made encouraging

Weight Watchers Reports Q1 2026 Results Read More »

FDA Cracks Down on Telehealth Companies

News / John LaRosa

March 12, 2026 The FDA is finally cracking down on telehealth companies marketing compounded weight loss drugs, warning them not to imply their products are FDA-approved or that they manufacture the medications. Roughly 30% of the more than 70 telehealth companies warned in the past six months rely on just four nationwide “white-label” medical groups

FDA Cracks Down on Telehealth Companies Read More »

Herbalife’s Weight Loss Sales Remained Stable in 2025

News / John LaRosa

February 18, 2026 Based on the latest press release and annual report by Herbalife… The North America region reported net sales of $1.03 billion for the year ended December 31, 2025, down 2.0%. Worldwide weight management product sales declined 0.8% in 2025. North American sales, at $1.03 billion, accounted for 20.5% of total Herbalife sales.

Herbalife’s Weight Loss Sales Remained Stable in 2025 Read More »

FDA Approves Novo’s Wegovy Weight Loss Pill

News / John LaRosa

Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo

FDA Approves Novo’s Wegovy Weight Loss Pill Read More »

Novo Nordisk Lowers Weight Loss Drug Prices

News / John LaRosa

Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy

Novo Nordisk Lowers Weight Loss Drug Prices Read More »

Trump Cuts Deal To Lower Weight Loss Drug Prices

News / John LaRosa

Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for

Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »

Weight Watchers Reports 3rd Qtr. Results

News / John LaRosa

Nov. 6, 2025 According to WW management: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining

Weight Watchers Reports 3rd Qtr. Results Read More »

Weight Loss Pills Are On The Horizon

News / John LaRosa

Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting

Weight Loss Pills Are On The Horizon Read More »

Pfizer to Buy Weight-Loss Drug Developer Metsera

News / John LaRosa

Sept. 23, 2025 Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that provides a re-entry for the company into the market for obesity drugs. Pfizer on Monday said it will pay an initial $47.50 a share, or about $4.9 billion, for Metsera, a nearly 43% premium

Pfizer to Buy Weight-Loss Drug Developer Metsera Read More »